Physician profile
Rasheed Nemer
NPI 1467441469
$7,965.76
in general payments reported to CMS, 2019-2025
28 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $451 · 2021: $1,110 · 2022: $1,152 · 2023: $1,132 · 2024: $1,748 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,879 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,879.29 |
| Education | $124.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,478.67 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $1,039.38 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $946.62 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $837.25 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $484.69 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $462.18 | 2020-2023 | Myrbetriq, Veozah |
| Amgen INC. | $459.07 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $438.52 | 2019 | |
| Lilly USA, LLC | $307.14 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.13 | 2022-2025 | Xifaxan |
| Pfizer INC. | $215.84 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $196.14 | 2019-2023 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $180.39 | 2019-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.18 | 2021-2025 | Jardiance |
| Abbvie INC. | $111.31 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $60.77 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $46.67 | 2024 | |
| Genentech USA, INC. | $44.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $44.02 | 2021-2022 | |
| Edwards Lifesciences Corporation | $42.74 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ultragenyx Pharmaceutical INC. | $34.84 | 2022 | |
| Eisai INC. | $34.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.24 | 2019 | |
| Allergan, INC. | $24.01 | 2019 | |
| Medtronic, INC. | $18.14 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.86 | 2019 | |
| Neurocrine Biosciences, INC. | $15.46 | 2022 | |
| Daiichi Sankyo INC. | $13.70 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasheed Nemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.